Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15049692 | 1.00 | MAOA (0.31) | MAOAMAOBPOLL | |
| SCHEMBL15049597 | 1.00 | MAOA (0.31) | MAOAMAOBPOLL | |
| SCHEMBL1450862 | 0.77 | MAOA (0.33) | MAOAMAOB | |
| SCHEMBL25378607 | 0.74 | CYP19A1 (0.36) | — | |
| SCHEMBL20768167 | 0.74 | — | — | |
| SCHEMBL5206019 | 0.73 | MEN1 (0.41) | MAOAMAOBPOLL | |
| SCHEMBL14592022 | 0.73 | MEN1 (0.41) | MAOAMAOBPOLL | |
| SCHEMBL30290975 | 0.73 | MEN1 (0.41) | MAOAMAOBPOLL | |
| SCHEMBL15049437 | 0.69 | CNR2 (0.35) | — | |
| SCHEMBL7228249 | 0.69 | ATM (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013025628-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-02-21 | — | — | WO | claimed |
| EP-2788345-B1 | DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | CHIESI FARM SPA (IT) | 2020-06-10 | — | — | EP | disclosed |
| EP-3030560-B1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-06-21 | — | — | EP | disclosed |
| US-9663473-B2 | Benzimidazolyl-methyl urea derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-05-30 | — | — | US | disclosed |
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-07-14 | — | — | US | disclosed |
| EP-3030560-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd (CH) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015019325-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-02-12 | — | — | WO | disclosed |
| EP-2788345-A1 | DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTALEN-1-YL UREA AND THEIR USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT | Chiesi Farmaceutici S.p.A. (IT) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013025628-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200686-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | UTS2R, ADORA3, P2RX7 | MAOA 1555/4885MAOB 1422/4885POLL 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.